News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>CICC Raises 3SBIO (01530.HK) TP by 56.3%, Keeps Rating at Outperform
3SBIO (01530.HK) will grant Pfizer exclusive rights for the development, production and commercialization of its PD-1/VEGF bispecific antibody (SSGJ-707) outside China, CICC publis...
Reset
Send
The window will close in 5 seconds
<Research>CICC Raises 3SBIO (01530.HK) TP by 56.3%, Keeps Rating at Outperform
Close
Recommend
7
Positive
20
Negative
3
 
SHORT SELL
 
STOCK INFO

3SBIO (01530.HK)  +0.070 (+0.350%)    Short selling $111.28M; Ratio 7.922%   will grant Pfizer exclusive rights for the development, production and commercialization of its PD-1/VEGF bispecific antibody (SSGJ-707) outside China, CICC published a research report saying.

Pfizer will have the option for commercialization in the Chinese market. Therefore, the broker maintained its 2025/ 2026 adjusted earnings forecasts for 3SBIO at RMB2.41 billion/ RMB2.6 billion respectively, and raised its target price by 56.3% to $21.1, with rating kept at Outperform.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-23 16:25.)

Related NewsCMSI: 3SBIO (01530.HK) Expected to Benefit from Maturation in Immunology Assets; TP Raised to $25

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.